---
layout: default
title: Alemtuzumab
parent: 僅模型預測 (L5)
nav_order: 38
evidence_level: L5
indication_count: 0
---

# Alemtuzumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Alemtuzumab: Evaluation On Hold — No Predicted Indications Available

---

## One-Sentence Summary

Alemtuzumab (DrugBank ID: DB00087) is confirmed as a marketed product in Malaysia with at least one active product registration.
However, this evaluation **cannot be completed** as the Evidence Pack contains no TxGNN-predicted repurposing candidates, and two critical data gaps — missing mechanism of action (DG002) and missing safety warnings/contraindications (DG001, Blocking severity) — remain unresolved.
No repurposing decision can be rendered until these gaps are filled.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in this Evidence Pack |
| Predicted New Indication | None — no TxGNN predictions returned |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A (no repurposing candidate to evaluate) |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Not applicable — the `predicted_indications` array is empty in this Evidence Pack. TxGNN did not return any repurposing candidates for Alemtuzumab under the current data configuration. Without a predicted target indication, no mechanistic plausibility analysis can be conducted.

Compounding this issue, the drug's mechanism of action is flagged as a high-severity data gap (DG002). Without MOA data, even a qualitative assessment of potential new indications cannot be attempted.

Three prerequisite steps must be completed before this section can be populated:
1. Re-run the TxGNN prediction pipeline for Alemtuzumab and confirm at least one disease candidate is returned.
2. Retrieve MOA from the DrugBank API (DG002 remediation).
3. Resolve TFDA/NPRA safety warnings and contraindications (DG001 remediation, currently Blocking).

---

## Clinical Trial Evidence

Currently no related clinical trials registered — no predicted indication is available to search against.

---

## Literature Evidence

Currently no related literature available — no predicted indication is available to search against.

---

## Malaysia Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|----------------------|--------------|-------------|---------------------|
| (Not provided) | (Not provided) | (Not provided) | (Not provided) |

> **Note:** The NPRA query (Query Log ID 1, executed 2026-03-27) confirmed 1 active licence and `market_status: 已上市` (Marketed). However, all licence detail fields — authorisation number, product name, dosage form, and approved indication text — are empty in the current Evidence Pack. Full licence details should be retrieved directly from the NPRA product registration database.

---

## Cytotoxicity

Alemtuzumab is an anti-CD52 monoclonal antibody. Based on its known pharmacological class (CD52-targeting monoclonal antibody historically used in oncology indications such as chronic lymphocytic leukaemia), this section is included provisionally. Formal confirmation of antineoplastic classification requires DrugBank category data, which is currently unavailable (DG002).

| Item | Content |
|------|---------|
| Cytotoxicity Classification | Targeted biological therapy (Anti-CD52 monoclonal antibody) — pending DrugBank category confirmation |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |

---

## Safety Considerations

Please refer to the package insert for safety information.

> All safety fields — key warnings, contraindications, and drug-drug interactions — are either data gaps or returned no results in this Evidence Pack. DG001 (TFDA warnings/contraindications) is classified as **Blocking severity**, meaning no safety screening can proceed until this data is retrieved. Remediation path: download and parse the TFDA package insert PDF.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No TxGNN-predicted indications were returned for Alemtuzumab, and two critical data gaps (DG001: safety information, Blocking; DG002: MOA, High) prevent any meaningful repurposing or safety assessment from proceeding.

**To proceed, the following is needed:**

- **[Blocking] Resolve DG001:** Download the TFDA/NPRA package insert PDF and extract key warnings and contraindications before any safety screening can begin.
- **[High] Resolve DG002:** Query the DrugBank API for Alemtuzumab (DB00087) to retrieve mechanism of action data, required for mechanistic plausibility analysis.
- **[Critical] Re-run TxGNN predictions:** Investigate why `predicted_indications` returned an empty array — check whether Alemtuzumab's DrugBank ID is present in the knowledge graph node list and rerun the prediction pipeline.
- **[Required] Complete NPRA licence details:** Retrieve product name, dosage form, authorisation number, and approved indication text for the 1 registered Malaysian product.
- **[Subsequent]** Once a predicted indication is identified, conduct targeted evidence searches on ClinicalTrials.gov and PubMed, and reassign an evidence level (L1–L5).

---

> ⚠️ *This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

